Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

NCT01686945 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions

DRUG: semaglutide
DRUG: semaglutide
DRUG: semaglutide
DRUG: placebo
DRUG: placebo

Sponsor

Novo Nordisk A/S